

Richard Eastell

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2549315/richard-eastell-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

382
papers

33,750
citations

93
h-index

177
g-index

407
ext. papers

38,532
ext. citations

7.7
avg, IF

7.06
L-index

#	Paper	IF	Citations
382	Bone fragility in diabetes: novel concepts and clinical implications.. <i>Lancet Diabetes and Endocrinology,the</i> , 2022 ,	18.1	6
381	Improving the Hip Fracture Risk Prediction with a Statistical Shape-and-Intensity Model of the Proximal Femur.. <i>Annals of Biomedical Engineering</i> , 2022 , 50, 211	4.7	0
380	Personalised 3D Assessment of Trochanteric Soft Tissues Improves HIP Fracture Classification Accuracy.. <i>Annals of Biomedical Engineering</i> , 2022 , 50, 303	4.7	0
379	Osteoporosis in men.. <i>Lancet Diabetes and Endocrinology,the</i> , 2022 ,	18.1	2
378	Bisphosphonates and the risk of atypical femur fractures.. <i>Bone</i> , 2021 , 116297	4.7	2
377	Urinary calcium indices in primary hyperparathyroidism (PHPT) and familial hypocalciuric hypercalcaemia (FHH): which test performs best?. <i>Postgraduate Medical Journal</i> , 2021 , 97, 577-582	2	3
376	Pleiotropic associations of heterozygosity for the Z allele in the UK Biobank. <i>ERJ Open Research</i> , 2021 , 7,	3.5	3
375	Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and ICTX in blood. <i>Clinica Chimica Acta</i> , 2021 , 515, 16-20	6.2	8
374	The Effects of Type 1 Diabetes and Diabetic Peripheral Neuropathy on the Musculoskeletal System: A Case-Control Study. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 1048-1059	6.3	3
373	Selenium supplementation to improve bone health in postmenopausal women: the SeMS three-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2021 , 8, 1-38	1.7	
372	In Reply to "Risks of Hip and Nonvertebral Fractures in Patients With CKD". <i>American Journal of Kidney Diseases</i> , 2021 , 77, 546-547	7.4	
371	Effect of selenium supplementation on musculoskeletal health in older women: a randomised, double-blind, placebo-controlled trial. <i>The Lancet Healthy Longevity</i> , 2021 , 2, e212-e221	9.5	6
370	Bone turnover in pregnancy, measured by urinary CTX, is influenced by vitamin D supplementation and is associated with maternal bone health: findings from the Maternal Vitamin D Osteoporosis Study (MAVIDOS) trial. <i>American Journal of Clinical Nutrition</i> , 2021 , 114, 1600-1611	7	1
369	The role of static bone histomorphometry in diagnosing renal osteodystrophy. <i>Bone</i> , 2021 , 142, 115689	4.7	2
368	Vascular calcification relationship to vascular biomarkers and bone metabolism in advanced chronic kidney disease. <i>Bone</i> , 2021 , 143, 115699	4.7	10
367	Real-world bone turnover marker use: impact on treatment decisions and fracture. <i>Osteoporosis International</i> , 2021 , 32, 831-840	5.3	5
366	Clinical and biochemical characteristics of adults with hypophosphatasia attending a metabolic bone clinic. <i>Bone</i> , 2021 , 144, 115795	4.7	5

365	Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 236-243	6.3	4
364	Reference interval for albumin-adjusted calcium based on a large UK population. <i>Clinical Endocrinology</i> , 2021 , 94, 34-39	3.4	5
363	Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial. <i>British Journal of Cancer</i> , 2021 , 124, 1373-1378	8.7	1
362	Normocalcaemic hyperparathyroidism and primary hyperparathyroidism: least significant change for adjusted serum calcium. <i>European Journal of Endocrinology</i> , 2021 , 184, K7-K10	6.5	1
361	Biochemical markers of bone turnover in osteoporosis 2021 , 1545-1588		1
360	Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA-HD Study Extension. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 921-930	6.3	7
359	Effect of denosumab on osteolytic lesion activity after total hip arthroplasty: a single-centre, randomised, double-blind, placebo-controlled, proof of concept trial. <i>Lancet Rheumatology</i> , 2021 , 3, e195-e203	14.2	4
358	Development of the Bone Phenotype and microRNA Profile in Adults With Low-Density Lipoprotein Receptor-Related Protein 5-High Bone Mass (LRP5-HBM) Disease. <i>JBMR Plus</i> , 2021 , 5, e10534	3.9	
357	Prevention and management of osteoporosis. <i>Medicine</i> , 2021 , 49, 572-577	0.6	1
356	Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIIH-ASBMR SABRE Project. <i>Journal of Bone and Mineral Research</i> , 2021 ,	6.3	2
355	The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: A systematic review and meta-analysis update. <i>Bone</i> , 2020 , 137, 115457	4.7	39
354	Normocalcaemic Hyperparathyroidism: Study of its Prevalence and Natural History. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	24
353	Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension. <i>Bone</i> , 2020 , 134, 115268	4.7	25
352	A Pooled Analysis of Fall Incidence From Placebo-Controlled Trials of Denosumab. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 1014-1021	6.3	10
351	The prevalence and natural history of normocalcaemic hypoparathyroidism in a United Kingdom referral population. <i>Clinical Endocrinology</i> , 2020 , 93, 119-126	3.4	
350	The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis. <i>Bone</i> , 2020 , 136, 115336	4.7	7
349	Maternal pregnancy vitamin D supplementation increases offspring bone formation in response to mechanical loading: Findings from a MAVIDOS Trial sub-study. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2020 , 20, 4-11	1.3	1
348	Serum microRNAs as novel biomarkers for osteoporotic vertebral fractures. <i>Bone</i> , 2020 , 130, 115105	4.7	39

347	The risk of hip and non-vertebral fractures in patients with Parkinson's disease and parkinsonism: A systematic review and meta-analysis. <i>Bone</i> , 2020 , 132, 115173	4.7	7
346	Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	18
345	Dietary Selenium Intakes and Musculoskeletal Function in Very Old Adults: Analysis of the Newcastle 85+ Study. <i>Nutrients</i> , 2020 , 12,	6.7	1
344	Response to Letter to the Editor: "Normocalcemic Hyperparathyroidism: Study of its Prevalence and Natural History". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	3
343	Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 672-682	18.1	40
342	Bone Turnover Markers Do Not Predict Fracture Risk in Type 2 Diabetes. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 2363-2371	6.3	7
341	Establishing race-, gender- and age-specific reference intervals for pyridoxal 5'-phosphate in the NHANES population to better identify adult hypophosphatasia. <i>Bone</i> , 2020 , 141, 115577	4.7	7
340	Risks of Hip and Nonvertebral Fractures in Patients With CKD G3a-G5D: A Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2020 , 76, 521-532	7.4	11
339	Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. <i>New England Journal of Medicine</i> , 2020 , 383, 743-753	59.2	70
338	Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 ,	5.6	43
337	Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2916-2946	2.2	56
336	Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 767-775	18.1	23
335	Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 632-642	6.3	96
334	The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 3-21	6.3	45
333	Response Letter to the Editor-Diamond et al, JBMR. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 1185-1186	6.3	45
332	A multicenter study to evaluate harmonization of assays for N-terminal propeptide of type I procollagen (PINP): a report from the IFCC-IOF Joint Committee for Bone Metabolism. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 1546-1555	5.9	13
331	Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. <i>Bone</i> , 2019 , 124, 83-88	4.7	6
330	Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 1595-1622	5.6	259

329	Effect of vitamin D supplementation on free and total vitamin D: A comparison of Asians and Caucasians. <i>Clinical Endocrinology</i> , 2019 , 90, 222-231	3.4	8
328	Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates: A Meta-analysis. <i>JAMA Internal Medicine</i> , 2019 , 179, 1491-1500	11.5	39
327	A Vitamin D, Calcium and Leucine-Enriched Whey Protein Nutritional Supplement Improves Measures of Bone Health in Sarcopenic Non-Malnourished Older Adults: The PROVIDE Study. <i>Calcified Tissue International</i> , 2019 , 105, 383-391	3.9	12
326	Response to Letter to the Editor: "Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 3537-3538	5.6	5
325	Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 810-816	6.3	15
324	Discordant pattern of peripheral fractures in diabetes: a meta-analysis on the risk of wrist and ankle fractures. <i>Osteoporosis International</i> , 2019 , 30, 135-143	5.3	8
323	Bone: Microarchitecture of bone predicts fractures in older women. <i>Nature Reviews Endocrinology</i> , 2018 , 14, 255-256	15.2	5
322	Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 1302-1309	5.6	12
321	A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. <i>British Journal of Cancer</i> , 2018 , 118, 770-776	8.7	5
320	Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 634-642	6.3	30
319	Comparison of femoral strength and fracture risk index derived from DXA-based finite element analysis for stratifying hip fracture risk: A cross-sectional study. <i>Bone</i> , 2018 , 110, 386-391	4.7	9
318	Association of incident hip fracture with the estimated femoral strength by finite element analysis of DXA scans in the Osteoporotic Fractures in Men (MrOS) study. <i>Osteoporosis International</i> , 2018 , 29, 643-651	5.3	11
317	Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 1557-1565	12.7	53
316	Bone turnover markers after the menopause: T-score approach. <i>Bone</i> , 2018 , 111, 44-48	4.7	25
315	DIAGNOSIS OF ENDOCRINE DISEASE: Bone turnover markers: are they clinically useful?. <i>European Journal of Endocrinology</i> , 2018 , 178, R19-R31	6.5	60
314	Authors' Reply. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 2444	12.7	
313	Bone Turnover Markers 2018 , 116-127		2
312	Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 190-198	6.3	306

311	Biochemical Markers of Bone Turnover in Osteoporosis 2018 , 293-301		0
310	Determination of Free 25(OH)D Concentrations and Their Relationships to Total 25(OH)D in Multiple Clinical Populations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 3278-3288	5.6	55
309	Developing a toolkit for the assessment and monitoring of musculoskeletal ageing. <i>Age and Ageing</i> , 2018 , 47, iv1-iv19	3	20
308	Spatio-Temporal Atlas of Bone Mineral Density Ageing. <i>Lecture Notes in Computer Science</i> , 2018 , 720-728	0.9	1
307	Towards a toolkit for the assessment and monitoring of musculoskeletal ageing. <i>Age and Ageing</i> , 2018 , 47, 774-777	3	1
306	Development and validation of a subject-specific finite element model of the functional spinal unit to predict vertebral strength. <i>Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine</i> , 2017 , 231, 821-830	1.7	8
305	Thyroid Function Tests in the Reference Range and Fracture: Individual Participant Analysis of Prospective Cohorts. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2719-2728	5.6	27
304	Pain, Quality of Life, and Safety Outcomes of Kyphoplasty for Vertebral Compression Fractures: Report of a Task Force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1935-1944	6.3	21
303	Effect of age and gender on serum periostin: Relationship to cortical measures, bone turnover and hormones. <i>Bone</i> , 2017 , 99, 8-13	4.7	18
302	Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. <i>Journal of Clinical Densitometry</i> , 2017 , 20, 8-24	3.5	125
301	Anabolic treatment for osteoporosis: teriparatide. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2017 , 14, 173-178		21
300	Bone Turnover Markers: Use in Fracture Prediction. <i>Journal of Clinical Densitometry</i> , 2017 , 20, 346-352	3.5	30
299	Prevention and management of osteoporosis. <i>Medicine</i> , 2017 , 45, 565-569	0.6	7
298	Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. <i>Bone</i> , 2017 , 105, 11-17	4.7	269
297	Degenerative inter-vertebral disc disease osteochondrosis intervertebralis in Europe: prevalence, geographic variation and radiological correlates in men and women aged 50 and over. <i>Rheumatology</i> , 2017 , 56, 1189-1199	3.9	4
296	Use of bone turnover markers in postmenopausal osteoporosis. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 908-923	18.1	171
295	Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis. <i>BMC Musculoskeletal Disorders</i> , 2017 , 18, 267	2.8	10
294	Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 3-10	6.3	94

293	Postmenopausal osteoporosis. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16069	51.1	263
292	Determinants of the Maternal 25-Hydroxyvitamin D Response to Vitamin D Supplementation During Pregnancy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 5012-5020	5.6	27
291	Risk and Prevention of Fracture in Patients With Major Medical Illnesses: A Mini-Review. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 2069-2072	6.3	17
290	Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. <i>BMJ, The</i> , 2016 , 353, i3365	5.9	55
289	Raman Spectroscopic Analysis of Fingernail Clippings Can Help Differentiate Between Postmenopausal Women Who Have and Have Not Suffered a Fracture. <i>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders</i> , 2016 , 9, 109-16	2.3	8
288	Bone turnover markers: response to comments by Seeman and Nguyen. <i>Osteoporosis International</i> , 2016 , 27, 37	5.3	
287	Cortical-Bone Fragility--Insights from sFRP4 Deficiency in Pyle's Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2553-2562	59.2	87
286	Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial. <i>Osteoporosis International</i> , 2016 , 27, 309-18	5.3	6
285	Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 234-44	6.3	14
284	Bone Disease after Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016 , 11, 1282-96	6.9	64
283	Maternal gestational vitamin D supplementation and offspring bone health (MAVIDOS): a multicentre, double-blind, randomised placebo-controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2016 , 4, 393-402	18.1	142
282	Notice of Retraction: Jamal SA, et al. Effect of Nitroglycerin Ointment on Bone Density and Strength in Postmenopausal Women: A Randomized Trial. <i>JAMA. 2011;305(8):800-807. JAMA - Journal of the American Medical Association</i> , 2016 , 315, 418-9	27.4	3
281	The Initial Slope of the Variogram, Foundation of the Trabecular Bone Score, Is Not or Is Poorly Associated With Vertebral Strength. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 341-6	6.3	22
280	Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1767-73	6.3	19
279	Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia. <i>Orphanet Journal of Rare Diseases</i> , 2016 , 11, 160	4.2	27
278	Free 25-hydroxyvitamin D is low in obesity, but there are no adverse associations with bone health. <i>American Journal of Clinical Nutrition</i> , 2016 , 103, 1465-71	7	76
277	Normocalcaemic hypoparathyroidism: prevalence and effect on bone status in older women. The OPUS study. <i>Clinical Endocrinology</i> , 2015 , 82, 816-23	3.4	9
276	Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism 2015 , 489-497		

275	Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 3-23	6.3	680
274	Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 570-4	6.3	15
273	Bone density, microstructure and strength in obese and normal weight men and women in younger and older adulthood. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 920-8	6.3	128
272	FP638PERIPHERAL VASCULAR CALCIFICATION AND BONE CHANGES IN ADVANCED CHRONIC KIDNEY DISEASE USING HIGH RESOLUTION PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY (HR-pQCT). <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, iii286-iii287	4.3	
271	Subclinical thyroid dysfunction and fracture risk: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 2055-65	27.4	190
270	The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 934-44	6.3	152
269	Biochemical markers in bone disease 2015 , 1656-1662		1
268	Oxytocin, a new determinant of bone mineral density in post-menopausal women: analysis of the OPUS cohort. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E634-41	5.6	25
267	Statistical shape and appearance models in osteoporosis. <i>Current Osteoporosis Reports</i> , 2014 , 12, 163-73	5.4	18
266	Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. <i>Human Molecular Genetics</i> , 2014 , 23, 1923-33	5.6	113
265	Establishing reference intervals for bone turnover markers in healthy postmenopausal women in a nonfasting state. <i>BoneKEy Reports</i> , 2014 , 3, 573		21
264	Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 458-66	6.3	55
263	A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 4094-100	5.6	8
262	Type I collagen degradation during tissue repair: comparison of mechanisms following fracture and acute coronary syndromes. <i>Bone</i> , 2014 , 69, 1-5	4.7	5
261	Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 3570-9	5.6	233
260	Precision of high-resolution peripheral quantitative computed tomography measurement variables: influence of gender, examination site, and age. <i>Calcified Tissue International</i> , 2014 , 94, 191-201	3.9	37
259	Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 3561-9	5.6	778
258	Fragility fractures and osteoporosis in CKD: pathophysiology and diagnostic methods. <i>American Journal of Kidney Diseases</i> , 2014 , 63, 1049-59	7.4	40

257	Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 4546-54	5.6	89
256	Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1460-1468	21.7	51
255	The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: the OCEAN study. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 629-38	6.3	32
254	Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium. <i>Human Molecular Genetics</i> , 2014 , 23, 3054-68	5.6	78
253	Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 158-65	6.3	85
252	Prediction of incident hip fracture with the estimated femoral strength by finite element analysis of DXA Scans in the study of osteoporotic fractures. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 2594-300	6.3	56
251	THRA and DIO2 mutations are unlikely to be a common cause of increased bone mineral density in euthyroid post-menopausal women. <i>European Journal of Endocrinology</i> , 2014 , 170, 637-44	6.5	7
250	Distribution of bone density and cortical thickness in the proximal femur and their association with hip fracture in postmenopausal women: a quantitative computed tomography study. <i>Osteoporosis International</i> , 2014 , 25, 251-63	5.3	52
249	Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice. <i>Osteoporosis International</i> , 2013 , 24, 941-7	5.3	27
248	Goal-directed treatment of osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 433-8	6.3	47
247	Osteoporosis in men. <i>Nature Reviews Endocrinology</i> , 2013 , 9, 637-45	15.2	26
246	Is it time to combine osteoporosis therapies?. <i>Lancet, The</i> , 2013 , 382, 5-7	4.0	3
245	Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study. <i>Osteoporosis International</i> , 2013 , 24, 321-8	5.3	18
244	Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial. <i>Osteoporosis International</i> , 2013 , 24, 329-38	5.3	16
243	Added value of trabecular bone score to bone mineral density for prediction of osteoporotic fractures in postmenopausal women: the OPUS study. <i>Bone</i> , 2013 , 57, 232-6	4.7	96
242	Vitamin D status in professional ballet dancers: winter vs. summer. <i>Journal of Science and Medicine in Sport</i> , 2013 , 16, 388-91	4.4	42
241	Identification and management of osteoporosis in older adults. <i>Medicine</i> , 2013 , 41, 47-52	0.6	6
240	Renal safety in patients treated with bisphosphonates for osteoporosis: a review. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 2049-59	6.3	67

239	Circulating serotonin and bone density, structure, and turnover in carcinoid syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 2902-7	5.6	14
238	Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 1519-28	5.6	79
237	BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 1319-27	6.3	39
236	Use of DXA-based finite element analysis of the proximal femur in a longitudinal study of hip fracture. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 1014-21	6.3	67
235	Biochemical Markers of Bone Turnover in Osteoporosis 2013 , 297-306		14
234	Mifepristone reduces insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels of cortisol: a pilot study. <i>PLoS ONE</i> , 2013 , 8, e60984	3.7	32
233	FRAX [®] : prediction of major osteoporotic fractures in women from the general population: the OPUS study. <i>PLoS ONE</i> , 2013 , 8, e83436	3.7	32
232	Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 687-93	6.3	139
231	Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 211-8	6.3	103
230	Distribution of bone density in the proximal femur and its association with hip fracture risk in older men: the osteoporotic fractures in men (MrOS) study. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 2314-24	6.3	47
229	Lipid profiles within the SABRE trial of anastrozole with and without risedronate. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 1141-7	4.4	6
228	Supine vs decubitus lateral patient positioning in vertebral fracture assessment. <i>Journal of Clinical Densitometry</i> , 2012 , 15, 454-460	3.5	5
227	Tree-structured subgroup analysis of receiver operating characteristic curves for diagnostic tests. <i>Academic Radiology</i> , 2012 , 19, 1529-36	4.3	7
226	Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. <i>Nature Genetics</i> , 2012 , 44, 491-501	36.3	866
225	Bone turnover and bone mineral density are independently related to selenium status in healthy euthyroid postmenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 4061-70	5.6	64
224	Heart drugs that affect bone. <i>Trends in Endocrinology and Metabolism</i> , 2012 , 23, 163-8	8.8	15
223	Bone turnover markers: use in osteoporosis. <i>Nature Reviews Rheumatology</i> , 2012 , 8, 379-89	8.1	157
222	Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study. <i>Bone</i> , 2012 , 50, 885-92	4.7	23

221	Reference intervals of bone turnover markers in healthy premenopausal women: results from a cross-sectional European study. <i>Bone</i> , 2012 , 50, 1141-7	4.7	55
220	Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis. <i>Bone</i> , 2012 , 50, 1135-40	4.7	6
219	Osteoporosis in men: an Endocrine Society clinical practice guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 1802-22	5.6	370
218	Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 3522-9	5.6	39
217	Esophageal and gastric cancer incidence and mortality in alendronate users. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 679-86	6.3	46
216	The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 243-54	6.3	397
215	Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 1487-93	6.3	11
214	Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 1627-34	6.3	92
213	WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. <i>PLoS Genetics</i> , 2012 , 8, e1002745	6	192
212	Cortical consolidation of the radius and tibia in young men and women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 3342-8	5.6	25
211	Bisphosphonates for postmenopausal osteoporosis. <i>Bone</i> , 2011 , 49, 82-8	4.7	99
210	Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 1303-12	6.3	103
209	International variation in proximal femur bone mineral density. <i>Osteoporosis International</i> , 2011 , 22, 721-9	5.3	18
208	Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide. <i>Osteoporosis International</i> , 2011 , 22, 1927-34	5.3	10
207	Effects of calcium-fortified ice cream on markers of bone health. <i>Osteoporosis International</i> , 2011 , 22, 2721-31	5.3	16
206	Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 530-7	6.3	155
205	Differential effects of teriparatide on regional bone formation using (18)F-fluoride positron emission tomography. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 1002-11	6.3	59
204	Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 1662-9	6.3	64

203	Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 1627-37	6.3	146
202	Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 1721-8	6.3	53
201	Effects of antiresorptive treatment on nonvertebral fracture outcomes. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 2411-8	6.3	36
200	Dietary phosphate modulates atherogenesis and insulin resistance in apolipoprotein E knockout mice--brief report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011 , 31, 1988-90	9.4	24
199	Effect of stopping risedronate after long-term treatment on bone turnover. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 3367-73	5.6	61
198	International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011 , 49, 1271-1274	5.9	209
197	Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 800-7	27.4	50
196	Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. <i>PLoS Genetics</i> , 2011 , 7, e1001372	6	199
195	Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. <i>Annals of Oncology</i> , 2011 , 22, 857-862	10.3	66
194	Proton pump inhibitor use and the antifracture efficacy of alendronate. <i>Archives of Internal Medicine</i> , 2011 , 171, 998-1004		60
193	Hormonal determinants of bone turnover before and after attainment of peak bone mass. <i>Clinical Endocrinology</i> , 2010 , 72, 320-7	3.4	17
192	Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. <i>Circulation</i> , 2010 , 122, 1716-24	16.7	34
191	Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 967-75	2.2	175
190	Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1706-15	9.7	119
189	Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. <i>New England Journal of Medicine</i> , 2010 , 362, 1761-71	59.2	383
188	Lasofoxifene in postmenopausal women with osteoporosis. <i>New England Journal of Medicine</i> , 2010 , 362, 686-96	59.2	295
187	Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 3173-81	5.6	136
186	Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 5258-65	5.6	128

185	Performance of quantitative ultrasound measurements of bone for monitoring raloxifene therapy. <i>Journal of Clinical Densitometry</i> , 2010 , 13, 441-50	3.5	4
184	The effect of a fortified milk drink on vitamin D status and bone turnover in post-menopausal women from South East Asia. <i>Bone</i> , 2010 , 46, 759-67	4.7	50
183	The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women. <i>Bone</i> , 2010 , 46, 592-7	4.7	25
182	Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. <i>Bone</i> , 2010 , 46, 929-34	4.7	25
181	Depot medroxyprogesterone acetate use after peak bone mass is associated with increased bone turnover but no decrease in bone mineral density. <i>Fertility and Sterility</i> , 2010 , 93, 697-701	4.8	7
180	Cardiovascular disease and bone. <i>Archives of Biochemistry and Biophysics</i> , 2010 , 503, 78-83	4.1	26
179	A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 32-40	6.3	49
178	Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 463-71	6.3	78
177	Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. <i>Osteoporosis International</i> , 2010 , 21, 1277-85 ^{5.3}	5.3	37
176	Individual susceptibility to periprosthetic osteolysis is associated with altered patterns of innate immune gene expression in response to pro-inflammatory stimuli. <i>Journal of Orthopaedic Research</i> , 2010 , 28, 1127-35	3.8	34
175	Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. <i>Journal of the American Geriatrics Society</i> , 2010 , 58, 292-9	5.6	91
174	More on reports of esophageal cancer with oral bisphosphonate use. <i>New England Journal of Medicine</i> , 2009 , 360, 1789; author reply 1791-2	59.2	66
173	Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3215-25	5.6	75
172	Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 340-50	5.6	222
171	Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. <i>Arthritis and Rheumatism</i> , 2009 , 60, 3346-55		319
170	Reply to letter by Gallo and Petrek commenting on interleukin-1 receptor antagonist and interleukin-6 polymorphisms and post-total hip arthroplasty osteolysis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 3856-7		3
169	Increase in vertebral fracture risk in postmenopausal women using omeprazole. <i>Calcified Tissue International</i> , 2009 , 84, 13-9	3.9	90
168	Bone turnover markers: a key tool for understanding osteoporosis. <i>Osteoporosis International</i> , 2009 , 20 Suppl 3, S237-8	5.3	5

167	Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 389-97	6.3	116
166	Use of DXA-based structural engineering models of the proximal femur to discriminate hip fracture. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 33-42	6.3	54
165	Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 726-36	6.3	125
164	Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 1095-102	6.3	275
163	Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 1544-51	6.3	94
162	Defining a Reference Population—No Easy Task. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 1639-1639	6.3	1
161	Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 2032-8	6.3	101
160	A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. <i>Bone</i> , 2009 , 45, 1044-52	4.7	37
159	Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. <i>Bone</i> , 2009 , 45, 1053-8	4.7	126
158	Denosumab for prevention of fractures in postmenopausal women with osteoporosis. <i>New England Journal of Medicine</i> , 2009 , 361, 756-65	59.2	2189
157	Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. <i>Lancet, The</i> , 2009 , 373, 1016-24	4.0	580
156	Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis. <i>Obstetrical and Gynecological Survey</i> , 2009 , 64, 805-807	2.4	6
155	Bone mineral density and biochemical marker response rates in postmenopausal women after treatment with zoledronic acid. <i>Bone</i> , 2008 , 42, S69	4.7	
154	Bone turnover markers: an appreciation of the contribution of Dr. P.D. Delmas. <i>Bone</i> , 2008 , 43, 649-52	4.7	
153	Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. <i>Cancer Treatment Reviews</i> , 2008 , 34 Suppl 1, S3-18	14.4	187
152	Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. <i>Lancet Oncology, The</i> , 2008 , 9, 866-72	21.7	154
151	Shape, structural properties, and cortical stability along the femoral neck: a study using clinical QCT. <i>Journal of Clinical Densitometry</i> , 2008 , 11, 373-82	3.5	11
150	Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1051-7	2.2	312

149	Effects of Depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 1317-23	5.6	40
148	The effects of tibolone in older postmenopausal women. <i>New England Journal of Medicine</i> , 2008 , 359, 697-708	59.2	308
147	Biomarkers of bone health and osteoporosis risk. <i>Proceedings of the Nutrition Society</i> , 2008 , 67, 157-62	2.9	131
146	Calcium supplementation and bone mineral accretion in adolescent girls: an 18-mo randomized controlled trial with 2-y follow-up. <i>American Journal of Clinical Nutrition</i> , 2008 , 87, 455-62	7	48
145	Risk factors for vertebral and nonvertebral fracture over 10 years: a population-based study in women. <i>Journal of Bone and Mineral Research</i> , 2008 , 23, 75-85	6.3	50
144	Comparison of densitometric and radiographic vertebral fracture assessment using the algorithm-based qualitative (ABQ) method in postmenopausal women at low and high risk of fracture. <i>Journal of Bone and Mineral Research</i> , 2008 , 23, 103-11	6.3	39
143	Algorithm-based qualitative and semiquantitative identification of prevalent vertebral fracture: agreement between different readers, imaging modalities, and diagnostic approaches. <i>Journal of Bone and Mineral Research</i> , 2008 , 23, 417-24	6.3	53
142	Polymorphisms in the interleukin-1 receptor antagonist and interleukin-6 genes affect risk of osteolysis in patients with total hip arthroplasty. <i>Arthritis and Rheumatism</i> , 2008 , 58, 3157-65		63
141	Optimal Thresholds, Linear or Nonlinear Relationships of Fracture Risk Reduction With Therapy. <i>Journal of Bone and Mineral Research</i> , 2008 , 23, 1350-1350	6.3	7
140	Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 1296-304	5.6	151
139	Treating osteoporosis. <i>Foundation Years</i> , 2007 , 3, 216-218		
138	Biochemical Markers of Bone Turnover 2007 , 337-349		1
137	Variation in the secreted frizzled-related protein-3 gene and risk of osteolysis and heterotopic ossification after total hip arthroplasty. <i>Journal of Orthopaedic Research</i> , 2007 , 25, 1665-70	3.8	32
136	Identification of vertebral fracture and non-osteoporotic short vertebral height in men: the MrOS study. <i>Journal of Bone and Mineral Research</i> , 2007 , 22, 1434-41	6.3	50
135	Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. <i>Journal of Bone and Mineral Research</i> , 2007 , 22, 1656-60	6.3	58
134	Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. <i>New England Journal of Medicine</i> , 2007 , 356, 1809-22	59.2	2094
133	Standardised quantitative morphometry: a modified approach for quantitative identification of prevalent vertebral deformities. <i>Osteoporosis International</i> , 2007 , 18, 1411-9	5.3	10
132	Breast cancer and the risk of osteoporotic fracture: A paradox. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 42-3	5.6	6

131	Milk supplementation and bone health in young adult chinese women. <i>Journal of Womens Health</i> , 2007 , 16, 692-702	3	21
130	Skeletal Health in Adulthood. <i>Hormone Research in Paediatrics</i> , 2007 , 67, 23-27	3.3	1
129	Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. <i>European Journal of Cancer</i> , 2007 , 43, 2523-31	7.5	75
128	Aromatase inhibitors and bone. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007 , 106, 157-61	5.1	14
127	Influence of bone quality on the strength of internal and external fixation of tibial plateau fractures. <i>Journal of Orthopaedic Research</i> , 2006 , 24, 2080-6	3.8	25
126	Does warfarin increase the risk of osteoporotic fracture?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006 , 2, 484-5		2
125	Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. <i>Current Medical Research and Opinion</i> , 2006 , 22, 61-6	2.5	95
124	Bone markers and current laboratory assays. <i>Cancer Treatment Reviews</i> , 2006 , 32 Suppl 1, 7-14	14.4	24
123	Treating osteoporosis. <i>Womens Health Medicine</i> , 2006 , 3, 171-172		
122	Precision of periprosthetic bone mineral density measurements using Hologic Windows versus DOS-based analysis software. <i>Journal of Clinical Densitometry</i> , 2006 , 9, 363-6	3.5	5
121	Adaptation of the Carter method to adjust lumbar spine bone mineral content for age and body size: application to children who were born preterm. <i>Journal of Clinical Densitometry</i> , 2006 , 9, 114-9	3.5	12
120	Measurement of Biochemical Markers of Bone Formation 2006 , 529-540		
119	Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). <i>Journal of Bone and Mineral Research</i> , 2006 , 21, 1215-23	6.3	249
118	Changes in bone mass and bone turnover following tibial shaft fracture. <i>Osteoporosis International</i> , 2006 , 17, 364-72	5.3	98
117	Device-specific thresholds to diagnose osteoporosis at the proximal femur: an approach to interpreting peripheral bone measurements in clinical practice. <i>Osteoporosis International</i> , 2006 , 17, 1293-302	5.3	37
116	Measurement of Biochemical Markers of Bone Formation 2006 , 529-540		2
115	Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 6323-31	5.6	181
114	Monitoring alendronate and estradiol therapy with quantitative ultrasound and bone mineral density. <i>Journal of Clinical Densitometry</i> , 2005 , 8, 278-86	3.5	25

113	Long-term effects of aromatase inhibitors on bone. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005 , 95, 151-4	5.1	53
112	Effect of temperature on the longitudinal variability of quantitative ultrasound variables. <i>Journal of Clinical Densitometry</i> , 2005 , 8, 436-44	3.5	12
111	Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 557-63	6.3	359
110	Polyethylene wear rate and osteolysis: critical threshold versus continuous dose-response relationship. <i>Journal of Orthopaedic Research</i> , 2005 , 23, 520-5	3.8	72
109	Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial. <i>Journal of Orthopaedic Research</i> , 2005 , 23, 1-8	3.8	58
108	How to interpret surrogate markers of efficacy in osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 1261-2; author reply 1263-4	6.3	3
107	Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 1514-24	6.3	172
106	Potential role of pancreatic and enteric hormones in regulating bone turnover. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 1497-506	6.3	68
105	Identification of vertebral fractures: an update. <i>Osteoporosis International</i> , 2005 , 16, 717-28	5.3	147
104	The discriminative ability of peripheral and axial bone measurements to identify proximal femoral, vertebral, distal forearm and proximal humeral fractures: a case control study. <i>Osteoporosis International</i> , 2005 , 16, 1794-802	5.3	35
103	Vitamin D and Osteoporosis 2005 , 1101-1120		7
102	A novel EXT1 splice site mutation in a kindred with hereditary multiple exostosis and osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 5386-92	5.6	17
101	Management of bone health in postmenopausal women. <i>Hormone Research in Paediatrics</i> , 2005 , 64 Suppl 2, 76-80	3.3	7
100	Role of oestrogen in the regulation of bone turnover at the menarche. <i>Journal of Endocrinology</i> , 2005 , 185, 223-34	4.7	113
99	Calcium Requirements During Treatment of Osteoporosis in Women 2005 , 425-431		
98	Pathogenesis of Transplantation Bone Disease: A Unifying Hypothesis 2005 , 209-217		
97	Efficacy of risedronate on clinical vertebral fractures within six months. <i>Current Medical Research and Opinion</i> , 2004 , 20, 433-9	2.5	150
96	The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 1117-23	5.6	264

95	A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. <i>Archives of Internal Medicine</i> , 2004 , 164, 871-9		59
94	Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. <i>Journal of the American Geriatrics Society</i> , 2004 , 52, 1832-9	5.6	145
93	Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS Study. <i>Journal of Bone and Mineral Research</i> , 2004 , 19, 782-93	6.3	197
92	Risk Assessment and Fracture Discrimination by Ultrasound: The Debate Continues. <i>Journal of Bone and Mineral Research</i> , 2004 , 20, 539-540	6.3	2
91	Attainment of peak bone mass at the lumbar spine, femoral neck and radius in men and women: relative contributions of bone size and volumetric bone mineral density. <i>Osteoporosis International</i> , 2004 , 15, 263-73	5.3	146
90	Comparison of methods for the visual identification of prevalent vertebral fracture in osteoporosis. <i>Osteoporosis International</i> , 2004 , 15, 887-96	5.3	209
89	Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. <i>Journal of Clinical Densitometry</i> , 2004 , 7, 255-61	3.5	185
88	Accuracy and precision of peripheral quantitative computed tomography measurements at the tibial metaphysis. <i>Journal of Clinical Densitometry</i> , 2004 , 7, 209-17	3.5	21
87	Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. <i>Bone</i> , 2004 , 34, 187-94	4.7	115
86	A Placebo Controlled Randomized Trial of Chromium Picolinate Supplementation on Indices of Bone and Calcium Metabolism in Healthy Women 2004 , 141-152		
85	11beta-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 3874-7	5.6	81
84	Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 4867-73	5.6	86
83	Biochemical Markers of Bone Turnover and Fracture Prediction. <i>The Journal of the British Menopause Society</i> , 2003 , 9, 10-16		2
82	Seasonal Variation Present and Biologically Significant?. <i>Journal of Bone and Mineral Research</i> , 2003 , 19, 170-171	6.3	
81	Variation in the TNF gene promoter and risk of osteolysis after total hip arthroplasty. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 1995-2001	6.3	65
80	The renal clearance of free and peptide-bound deoxypyridinoline: response to pamidronate treatment of Paget's disease. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 658-61	6.3	10
79	Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 1051-6	6.3	458
78	Absence of marked seasonal change in bone turnover: a longitudinal and multicenter cross-sectional study. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 1274-81	6.3	55

77	Effect of pamidronate on excretion of pyridinium crosslinks of collagen after total hip arthroplasty. <i>Calcified Tissue International</i> , 2003 , 73, 326-31	3.9	4
76	Management of osteoporosis due to ovarian failure. <i>Medical and Pediatric Oncology</i> , 2003 , 41, 222-7		24
75	Biochemical markers of bone turnover and development of heterotopic ossification after total hip arthroplasty. <i>Journal of Orthopaedic Research</i> , 2003 , 21, 529-34	3.8	37
74	Bone mineral density and biochemical markers of bone turnover in aseptic loosening after total hip arthroplasty. <i>Journal of Orthopaedic Research</i> , 2003 , 21, 691-6	3.8	77
73	Differential effects of androgens and estrogens on bone turnover in normal men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 204-10	5.6	239
72	Evaluation of serum concentrations of biochemical markers of bone metabolism and insulin-like growth factor I associated with treadmill exercise in young horses. <i>American Journal of Veterinary Research</i> , 2003 , 64, 1549-56	1.1	34
71	Biochemical markers of bone turnover and fracture prediction. <i>The Journal of the British Menopause Society</i> , 2003 , 9, 10-5		26
70	Laboratory Assessment of Skeletal Status 2003 , 77-82		
69	Bone turnover markers in clinical practice 2002 , 99-114		
68	Diet and healthy bones. <i>Calcified Tissue International</i> , 2002 , 70, 400-4	3.9	56
67	Acute changes of bone turnover and PTH induced by insulin and glucose: euglycemic and hypoglycemic hyperinsulinemic clamp studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 3324-9	5.6	66
66	Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 3609-17	5.6	415
65	Strategies for skeletal health in the elderly. <i>Proceedings of the Nutrition Society</i> , 2002 , 61, 173-80	2.9	35
64	Assessment and Recommendations on Factors Contributing to Preanalytical Variability of Urinary Pyridinoline and Deoxypyridinoline. <i>Clinical Chemistry</i> , 2002 , 48, 220-235	5.5	39
63	Biochemical Markers of Bone Metabolism 2002 , 1543-1571		3
62	Assessment and recommendations on factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinoline. <i>Clinical Chemistry</i> , 2002 , 48, 220-35	5.5	7
61	A single nucleotide polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women. <i>Human Genetics</i> , 2001 , 108, 233-6	6.3	154
60	Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial. <i>Journal of Bone and Mineral Research</i> , 2001 , 16, 556-64	6.3	78

59	Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2001 , 94, 575-97	2.7	49
58	Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. <i>New England Journal of Medicine</i> , 2001 , 344, 333-40	59.2	1530
57	Intrauterine programming of adult body composition. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 267-72	5.6	256
56	Glucocorticoid-induced osteoporosis. <i>Current Opinion in Rheumatology</i> , 2001 , 13, 326-32	5.3	46
55	Calcium Requirements During Treatment of Osteoporosis in Women 2001 , 307-321		1
54	Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. <i>Osteoporosis International</i> , 2000 , 11, 331-7	5.3	106
53	Measurement of osteocalcin. <i>Annals of Clinical Biochemistry</i> , 2000 , 37 (Pt 4), 432-46	2.2	178
52	The role of bone turnover markers and risk factors in the assessment of osteoporosis and fracture risk. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2000 , 14, 213-32	6.5	12
51	Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. <i>Journal of Clinical Investigation</i> , 2000 , 106, 1553-60	15.9	537
50	Optimising the Benefits of Hormone Replacement Therapy for Osteoporosis. <i>The Journal of the British Menopause Society</i> , 1999 , 5, 20-23		
49	Serum Galactosyl Hydroxylysine as a Biochemical Marker of Bone Resorption. <i>Clinical Chemistry</i> , 1999 , 45, 676-681	5.5	23
48	Optimization of glucocorticoid replacement therapy: the long-term effect on bone mineral density. <i>Clinical Endocrinology</i> , 1999 , 50, 815-7	3.4	9
47	Rate of Loss Recalculated. <i>Journal of Bone and Mineral Research</i> , 1999 , 14, 1991	6.3	
46	Variability and response of urinary resorption markers to hormone replacement therapy. <i>Journal of Bone and Mineral Research</i> , 1999 , 14, 471-2	6.3	5
45	Monitoring alendronate therapy for osteoporosis. <i>Journal of Bone and Mineral Research</i> , 1999 , 14, 602-86.3		56
44	Zinc supplementation and bone growth in pubertal girls. <i>Lancet, The</i> , 1999 , 354, 485	4.0	15
43	Bone turnover in preterm infants. <i>Pediatric Research</i> , 1999 , 45, 363-6	3.2	31
42	Biochemical markers of bone turnover. <i>Current Opinion in Nephrology and Hypertension</i> , 1999 , 8, 421-7	3.5	24

41	Effects of estrogen therapy of postmenopausal women on cytokines measured in peripheral blood. <i>Journal of Bone and Mineral Research</i> , 1998 , 13, 1577-86	6.3	44
40	A longitudinal study of bone gain in pubertal girls: anthropometric and biochemical correlates. <i>Journal of Bone and Mineral Research</i> , 1998 , 13, 1602-12	6.3	120
39	Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. <i>Journal of Bone and Mineral Research</i> , 1998 , 13, 1124-33	6.3	198
38	A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. <i>Journal of Internal Medicine</i> , 1998 , 244, 271-92	10.8	243
37	Mechanisms of bone loss after cardiac transplantation. <i>Bone</i> , 1998 , 22, 267-71	4.7	62
36	Bone mass and muscle strength in female college athletes (runners and swimmers). <i>Mayo Clinic Proceedings</i> , 1998 , 73, 1151-60	6.4	65
35	Treatment of postmenopausal osteoporosis. <i>New England Journal of Medicine</i> , 1998 , 338, 736-46	59.2	515
34	Bone Metabolism and Osteoporosis. <i>The Journal of the British Menopause Society</i> , 1998 , 4, 103-106		1
33	Bone Growth in Childhood and Adolescence: The Interpretation of Dietary Supplementation Trials 1998 , 50-55		
32	Adaptation of Young Men to High Phosphate Intake 1998 , 185-190		1
31	Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 658-65	5.6	65
30	The performance and utility of biochemical markers of bone turnover: do we know enough to use them in clinical practice?. <i>Annals of Clinical Biochemistry</i> , 1997 , 34 (Pt 5), 449-59	2.2	41
29	Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. <i>Clinical Endocrinology</i> , 1997 , 46, 301-7	3.4	52
28	Glucocorticoid replacement therapy: are patients over treated and does it matter?. <i>Clinical Endocrinology</i> , 1997 , 46, 255-61	3.4	147
27	Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled intervention trial. <i>BMJ: British Medical Journal</i> , 1997 , 315, 1255-60		451
26	Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. <i>Cancer Treatment Reviews</i> , 1996 , 22, 289-331	14.4	104
25	Management of corticosteroid-induced osteoporosis. UK Consensus Group Meeting on Osteoporosis. <i>Journal of Internal Medicine</i> , 1995 , 237, 439-47	10.8	98
24	Diclofenac sodium inhibits bone resorption in postmenopausal women. <i>American Journal of Medicine</i> , 1994 , 96, 349-53	2.4	43

23	Stable strontium absorption as a measure of intestinal calcium absorption: comparison with the double-radiotracer calcium absorption test. <i>Clinical Science</i> , 1994 , 87, 363-8	6.5	26
22	Measurement of bone mass and turnover. <i>Baillieres Clinical Rheumatology</i> , 1993 , 7, 479-98		17
21	Risk of fractures in patients with pernicious anemia. <i>Journal of Bone and Mineral Research</i> , 1992 , 7, 573-96.3		79
20	Pernicious anaemia as a risk factor for osteoporosis. <i>Clinical Science</i> , 1992 , 82, 681-5	6.5	49
19	Nyctohemeral changes in bone turnover assessed by serum bone Gla-protein concentration and urinary deoxypyridinoline excretion: effects of growth and ageing. <i>Clinical Science</i> , 1992 , 83, 375-82	6.5	95
18	Markers of bone and collagen breakdown in early inflammatory arthritis. <i>Baillieres Clinical Rheumatology</i> , 1992 , 6, 351-72		7
17	Interrelationship among vitamin D metabolism, true calcium absorption, parathyroid function, and age in women: evidence of an age-related intestinal resistance to 1,25-dihydroxyvitamin D action. <i>Journal of Bone and Mineral Research</i> , 1991 , 6, 125-32	6.3	141
16	Classification of vertebral fractures. <i>Journal of Bone and Mineral Research</i> , 1991 , 6, 207-15	6.3	428
15	Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. <i>Hepatology</i> , 1991 , 14, 296-300	11.2	261
14	Circadian variation in ionized calcium and intact parathyroid hormone: evidence for sex differences in calcium homeostasis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991 , 72, 69-76	5.6	116
13	The nocturnal increase in growth hormone is not the cause of the nocturnal increase in serum osteocalcin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991 , 73, 368-72	5.6	12
12	Proportion of human vertebral body bone that is cancellous. <i>Journal of Bone and Mineral Research</i> , 1990 , 5, 1237-41	6.3	63
11	Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. <i>Journal of Bone and Mineral Research</i> , 1990 , 5, 311-9	6.3	290
10	Recent studies of human calcium metabolism using stable isotopic tracers. <i>Canadian Journal of Physiology and Pharmacology</i> , 1990 , 68, 973-6	2.4	45
9	One-day test using stable isotopes to measure true fractional calcium absorption. <i>Journal of Bone and Mineral Research</i> , 1989 , 4, 463-8	6.3	63
8	Colles' fracture and bone density of the ultradistal radius. <i>Journal of Bone and Mineral Research</i> , 1989 , 4, 607-13	6.3	52
7	Comparison of polyethylene glycol and chromium-51 chloride as nonabsorbable stool markers in calcium balance studies. <i>Bone and Mineral</i> , 1989 , 6, 95-105		8
6	Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1988 , 67, 741-8	5.6	233

5	Diagnostic Evaluation of Osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 1988 , 17, 547-571	5.5	30
4	New approaches to the treatment of osteoporosis. <i>Clinical Obstetrics and Gynecology</i> , 1987 , 30, 860-70	1.7	8
3	Calcium Homeostasis and Osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 1987 , 16, 829-842	5.5	18
2	Treatment of Isolated Hypogonadotropic Hypogonadism Effect on Bone Mineral Density and Bone Turnover		35
1	Measurement of Osteocalcin		48